Docetaxel
Overview
Docetaxel is a chemotherapy medication that works by interfering with cell division, used primarily in the treatment of breast, lung, prostate, and other cancers. It is a semi-synthetic analogue of paclitaxel and functions as a microtubule inhibitor.
API suppliers (4)
Suppliers of Docetaxel evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
4 of 4 hold a GMP certificate on record in the EU or UK registers · 4 hold a European CEP for this substance
- INDENA SPAItalyCEP GMP on record
- MSN Laboratories Private LimitedIndiaCEP GMP on record
- SAMYANG HOLDINGS CORPSouth KoreaCEP GMP on record
- PHYTON BIOTECH LLCUnited StatesCEP GMP on record
Patent & exclusivity (US)
Per the FDA Orange Book (55 approved US products), the latest listed US patent on Docetaxel expires 16 May 2036. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Docetaxel? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.